Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Fatigue 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Brain Diseases 1Anxiety Disorders 1

Interventions

Rituximab 66Cyclophosphamide 52fludarabine phosphate 26fludarabine 22Filgrastim 21Vincristine 19Methotrexate 19Melphalan 19Doxorubicin 18Radiotherapy 17Etoposide 17Prednisone 16Tacrolimus 15Whole-Body Irradiation 14Mycophenolic Acid 14Cytarabine 14Peripheral Blood Stem Cell Transplantation 13Gemcitabine 13Cyclosporine 13Antilymphocyte Serum 13Lenalidomide 12Busulfan 11Bortezomib 11Granulocyte Colony-Stimulating Factor 9Alemtuzumab 9sargramostim 8Dexamethasone 8Cord Blood Stem Cell Transplantation 8pembrolizumab 7ibritumomab tiuxetan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma × Midazolam × Clear all
NCT01209832 2019-03-18

A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients

Eli Lilly and Company

Phase 1 Terminated
11 enrolled 10 charts
Lymphoid

Lymphoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡